Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of SAR566658 in CA6-positive metastatic triple negative breast cancer
2016-001962-27Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SAR566658 in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Objective response rate. Started Aug 2016; status: terminated.
02
Drugs
SAR566658
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2016-001962-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001962-27.